药物诱导性心律失常:美国心脏协会科学声明
该科学声明指出多种常用药物可诱发或加重心律失常,包括抗心律失常药、抗菌药、精神类药物、美沙酮等,部分药物延长QT间期并引发尖端扭转型室速。声明强调识别药物诱导性心律失常的重要性,管理包括停用致病药物并按指南治疗特定心律失常,高风险患者需加强监测。
要点
- 多种常用药物可诱发或加重心律失常,包括缓慢性心律失常、房颤/房扑、房速、AVNRT、单形性室速、Brugada综合征等。
- 尖端扭转型室速、单形性室速和Brugada综合征可能导致严重后果包括心脏性猝死。
- 管理包括停用致病药物并按指南治疗特定心律失常,不可纠正风险因素者需加强心电监测。
核心结论
- 许多广泛使用的药物可能诱发或加重多种心律失常,临床医生应认识到患者心律失常可能是药物诱导的。
研究设计与样本
- 美国心脏协会(AHA)科学声明,基于现有证据总结药物诱导性心律失常的类型、机制、风险因素和管理策略。
主要发现
- 抗心律失常药、抗菌药、精神类药物、美沙酮及其他治疗类别药物可延长QT间期并诱发尖端扭转型室速。
- 药物还可触发缓慢性心律失常、房颤/房扑、房速、房室结折返性心动过速、单形性室速和Brugada综合征。
- 部分药物诱导性心律失常(缓慢性心律失常、房速、AVNRT)主要因症状显著,而单形性室速、Brugada综合征、尖端扭转型室速可能导致心脏性猝死。
- 某些药物诱导性心律失常的机制已知,另一些则尚不清楚;尖端扭转型室速的风险因素已明确。
临床怎么用
- 识别可能引起心律失常的药物,并考虑患者心律失常为药物诱导的可能性。
- 尽可能纠正可改变的风险因素以预防和降低风险。
- 对不可纠正风险因素且需使用潜在致心律失常药物者,加强心电图等监测以早期发现和治疗。
- 管理包括停用致病药物并遵循特定心律失常的治疗指南;过量时可能需要针对性解毒策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Many widely used medications may cause or exacerbate a variety of arrhythmias. Numerous antiarrhythmic agents, antimicrobial drugs, psychotropic medications, and methadone, as well as a growing list of drugs from other therapeutic classes (neurological drugs, anticancer agents, and many others), can prolong the QT interval and provoke torsades de pointes. Perhaps less familiar to clinicians is the fact that drugs can also trigger other arrhythmias, including bradyarrhythmias, atrial fibrillation/atrial flutter, atrial tachycardia, atrioventricular nodal reentrant tachycardia, monomorphic ventricular tachycardia, and Brugada syndrome. Some drug-induced arrhythmias (bradyarrhythmias, atrial tachycardia, atrioventricular node reentrant tachycardia) are significant predominantly because of their symptoms; others (monomorphic ventricular tachycardia, Brugada syndrome, torsades de pointes) may result in serious consequences, including sudden cardiac death. Mechanisms of arrhythmias are well known for some medications but, in other instances, remain poorly understood. For some drug-induced arrhythmias, particularly torsades de pointes, risk factors are well defined. Modification of risk factors, when possible, is important for prevention and risk reduction. In patients with nonmodifiable risk factors who require a potentially arrhythmia-inducing drug, enhanced electrocardiographic and other monitoring strategies may be beneficial for early detection and treatment. Management of drug-induced arrhythmias includes discontinuation of the offending medication and following treatment guidelines for the specific arrhythmia. In overdose situations, targeted detoxification strategies may be needed. Awareness of drugs that may cause arrhythmias and knowledge of distinct arrhythmias that may be drug-induced are essential for clinicians. Consideration of the possibility that a patient's arrythmia could be drug-induced is important.
引用
- Tisdale JE, Chung MK, Campbell KB, et al. Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association. Circulation. 2020. PMID: 32929996. doi:10.1161/CIR.0000000000000905
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。